Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment

Research output: Patent

Abstract

In the instant invention, simvastatin (Sim) is used to modulate Vesicular Stomatitis Virus (VSV) infection at the level of viral replication for treatment of cancer. Both lipid-lowering and pleiotropic cellular effects of simvastatin are exploited in this modulation. Simvastatin upregulates the expression of Rae1 and Nup98, therefore altering normal cellular mRNA distribution and reverting VSV's mRNA export block. Furthermore, simvastatin causes redistribution of Flotillin-1, which affects VSV replication/budding. Simvastatin is further used as a neoadjuvant for the selective modulatory control of live VSV oncolytic therapy.
Original languageAmerican English
Patent numberUS9289456B2
StatePublished - Mar 22 2016

Fingerprint

Dive into the research topics of 'Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment'. Together they form a unique fingerprint.

Cite this